Issy Les Moulineaux (France), 20 February 2025 – An increasing number of scientific studies are highlighting the links between the composition and functionality of the gut microbiota and numerous pathologies such as cancer, cardiometabolic and autoimmune diseases. Analysis of the microbiota is becoming an essential element in the diagnosis, prevention and monitoring of pathologies, as well as in predicting the response to therapy.

GMT Science, an innovative French medtech company, is using standardised, high-resolution stool metagenomics and AI-driven data science to develop in vitro diagnostics. These tests make it possible to assess patients' gut microbiota from a simple stool sample: from identifying the microbial species present to the genes and functions they carry. This comprehensive mi-crobiome profiling combined with a proprietary AI-based algorithm ensures robust and repro-ducible analysis of microbiome data.

This new approach will enable doctors to make effective use of microbiome information in clinical settings, paving the way for personalised medicine and targeted therapies.

Etienne Formstecher, founder and CEO of GMT Science said: « Joining the virtual incubator of the Cerba HealthCare Group, a European leader in medical diagnostics, is a unique opportunity to finalise the development of our microbiome-based in vitro diagnostics in the fields of oncology and cardiometabolic diseases and to integrate them into the workflow of clinical pathology laboratories.».

Jérôme Sallette, Scientific director of Cerba HealthCare, added: « We are delighted to welcome GMT Science to our virtual incubator, this open innovation start-up support facility that we created in 2017. We were impressed by their scientific and medical approach to the clinical use of the microbiome. These promising developments will provide better care for patients suffering from chronic diseases (autoimmune diseases and IBD), but also for cancer patients as part of their immunotherapy.».